COPD Foundation and Evidera win the Best Personalized Medicine Advance or Application Award at Informa’s inaugural Clinical & Research Excellence Awards.
WASHINGTON, D.C. - April 28, 2016 - COPD Foundation and Evidera won the Best Personalized Medicine Advance or Application Award at the first annual Clinical & Research Excellence Awards. The Clinical and Research Excellence Awards – or CARE Awards – honor those who work in clinical research and development to make human lives better with new medicines. Run by Informa’s Pharma Intelligence, they are celebration of the brilliant minds, strategic thinkers and risk takers who bring the hope of good health to humankind.
The Best Personalized Medicine Advance or Application award recognized the efforts of a company working in the expanding and promising field of personalized medicine. The judges said this exemplified a successful public-private collaboration that established the first qualified biomarker for a clinical indication under the FDA’s Drug Development Tool program.
The Chronic Obstructive Pulmonary Disease (COPD) Biomarker Qualification Consortium (CBQC) is a unique public-private partnership among the COPD Foundation, the pharmaceutical industry, academic experts, and the Food and Drug Administration. The intent of the CBQC is to facilitate the qualification of biomarkers that can be used for enrichment of clinical trial populations and/or as outcome assessments. Recently, the FDA approved the qualification of plasma fibrinogen as a prognostic or enrichment biomarker for all-cause mortality and COPD exacerbations. Plasma fibrinogen is the first biomarker drug development tool qualified for use in COPD under the FDA’s Drug Development Tool (DDT) qualification program.
The awards were announced at a ceremony at the State Room in Boston on April 27, 2016.
Alex Shimmings, managing editor at Scrip Intelligence said: “The CARE Awards successfully gathered together distinguished leaders in the biopharmaceutical, CRO and diagnostic industries from all corners of the globe to celebrate the fantastic life-changing work being undertaken. This first year was an incredible success and we’re already looking forward to building on this next year.”